Ambry Genetics Announces Launch of their StemArray™ Product and Services for High Resolution Characterization of Human Stem Cells.

FOR IMMEDIATE RELEASE

Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Aliso Viejo, CA, January 20, 2010 - Ambry Genetics today introduces their new StemArray™ product and services utilizing aCGH technology to cover the entire genome. The Ambry StemArray™ offers a higher resolution approach to standard karyotyping for stem cells at comparable costs. The 44K array offers increased coverage in known stem cell and cancer associated genes to further enhance the resolution in these functionally important regions.

Human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells that are cultured for an extended period of time are susceptible to chromosomal instability, which is a big concern for researchers. Currently, stem cells have been characterized mainly through traditional low-resolution karyotypic analyses, which can only identify large scale aneuploidies over 5 MB in size. The Ambry StemArray™ has an average resolution of 43KB throughout the genome and 24KB in RefSeq genes. Resolution is even further enhanced, to the exonic level, in stem cells and cancer related genes

"The StemArray™ is the solution for stem cell scientists that are working with Human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells in order to detect genomic abnormalities found in stem cells that would be missed by low resolution karyotyping," said Ardy Arianpour, Ambry’s Director of Business Development. "We are offering the StemArray™ at a comparable cost to traditional karyotyping and strongly believe that the product and our service will help scientists with new discoveries within this market."

"As human stem cells begin to make their way into clinical studies, it is essential that the cell lines be thoroughly characterized," added Dr. Aaron Elliott, Ambry’s R&D Scientist, Genomics. "Using the StemArray™ scientists will not only detect the extremely large copy number changes that can be found by karyotype, but also identify very small aberrations that occur during culture that could decrease the reproducibility and reliability of experimental data."


About Ambry Genetics ®

Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer the most comprehensive genetic testing menu in the industry. Ambry is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. As part of the Konica Minolta family, Ambry is responsibly applying new technologies to the clinical molecular diagnostics market to bring about precision medicine. For more information about Ambry Genetics, visit www.ambrygen.com.

Press Contact:
Dina Scaglione
Director, Marketing
dscaglione@ambrygen.com
949 457 4355

Search Results

Start your search...